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Abstract
Development of vasogenic brain edema is a key event contributing to mortality after subarachnoid hemorrhage (SAH). The
precise underlying mechanisms at the neurovascular level that lead to disruption of the blood-brain barrier (BBB) are still
unknown. Activation of myosin light chain kinases (MLCK) may result in change of endothelial cell shape and opening of
the intercellular gap with subsequent vascular leakage. Male C57Bl6 mice were subjected to endovascular perforation. Brain
water content was determined by wet-dry ratio and BBB integrity by Evans-Blue extravasation. The specific MLCK inhibitor
ML-7 was administered to the mice to determine the role of the contractile apparatus of the neurovascular unit in determining
brain water content, BBB integrity, neurofunctional outcome, brain damage, and survival at 7 days after SAH. Inhibition of
MLCK significantly reduced BBB permeability (Evans Blue extravasation − 28%) and significantly decreased edema formation
in comparison with controls (− 2%). MLCK-treated mice showed reduced intracranial pressure (− 53%), improved neurological
outcome at 24 h and 48 h after SAH, and reduced 7-day mortality. Tight junction proteins claudin-5 and zonula occludens-1
levels were not influenced by ML-7 at 24 h after insult. The effect of ML-7 on pMLC was confirmed in brain endothelial cell
culture (bEnd.3 cells) subjected to 4-h oxygen-glucose deprivation. The present study indicates that MLCK contributes to blood-
brain barrier dysfunction after SAH by a mechanism that does not involve modulation of tight junction protein levels, but via
activation of the contractile apparatus of the endothelial cell skeleton. This underlying mechanism may be a promising target for
the treatment of SAH.
Keywords Subarachnoid hemorrhage . Brain edema . ML-7 .
Myosinlightchainkinases . Intracranialpressure .Blood-brain
barrier
Introduction
A critical factor for the 35% mortality rate in patients suffering
from subarachnoid hemorrhage (SAH) is the development of
severe global cerebral edema [1]. In human studies, brain edema
formation correlates with ischemic damage, cognitive deficits,
and mortality [1, 2]. Post-hemorrhagic brain edema is mostly
of vasogenic origin and results from the disruption of blood-
brain-barrier (BBB) integrity [3]. The precise underlying mech-
anisms leading to BBBbreakdown at the neurovascular level and
the significance of the endothelial cells for the development of
vasogenic brain edema after SAH are still unknown. Recent
in vitro studies suggest that the activation of the contractile ap-
paratus of endothelial cellsmay contribute to the disruption of the
BBB in pathologic conditions [4–6]. Data frommechanical brain
lesions indicate increased activity of myosin light chain kinase
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(MLCK) [7, 8] leading to the phosphorylation of regulatory my-
osin light chains (MLC). This finding was associated with the
loss of BBB integrity and worsening of brain edema.
The aim of the present study was to determine the role of
the cytoskeleton of vascular cells in BBB dysfunction, brain
edema formation, intracranial pressure regulation, and neuro-
logical recovery after experimental SAH.
Methods
Experimental Subarachnoid Hemorrhage
All animal experiments were conducted in compliance with in-
stitutional guidelines of the Johannes Gutenberg-University,
Ma in z . The An ima l E t h i c s Commi t t e e o f t h e
Landesuntersuchungsamt Rheinland-Pfalz approved all experi-
ments. One hundred thirty-six male C57Bl6N mice (weight
18–24 g, age 12–14 weeks, Charles River Laboratory, Sulzfeld,
Germany) had free access to food and water before and during
the experiments. After induction of anesthesia by intraperitoneal
injection of midazolam (5 mg/kg; Ratiopharm, Ulm, Germany),
fentanyl (0.05 mg/kg; CuraMed, Karlsruhe, Germany), and
medetomidin (0.5 mg/kg; Pfizer, Germany) animals were
intubated and mechanically ventilated under control of the end-
expiratory pCO2 levels with a mixture of 60% N2 and 40% O2
(Minivent, Hugo Sachs, Hugstetten, Germany).
SAHwas induced by the endovascular puncture technique as
previously described [9]. Rectal temperature was maintained at
37 °C with a thermostatically regulated, feedback-controlled
heating pad (Hugo-Sachs). Intracranial pressure (ICP) was con-
tinuously recorded from 10 min before SAH until 15 min after
SAH. ICP probe (Codman ICPmicrosensor, Johnson& Johnson
Medical Limited, Berkshire, UK) was placed on the contralateral
side 3 mm posterior of bregma. Regional cerebral blood flow
(CBF) was determined in the territory of the middle cerebral
artery (MCA) of the left hemisphere. A laser-Doppler flow
(LDF) glass fiber probe was fixed to the skull, and LDF was
determined with Periflux 4001 Master (Perimed, Stockholm,
Sweden) and recorded continuously (5-Hz sampling rate) from
10 min before SAH until 15 min after SAH.
For induction of SAH, animals were placed in the supine
position and the neck was incised along the midline. After prep-
aration of the left bifurcation of the external (ECA) and internal
carotid arteries (ICA), a 5-0 monofilament (Prolene, Ethicon,
Johnson & Johnson Medical Limited, Berkshire, UK) was ad-
vanced via the ECA into the ICA until a slight decrease of the
ipsilateral CBF was detected as indicated by LDF. This ensured
that the position of the tip of the filament was close to the bifur-
cation of the ICA, thus reducing the flow to the MCA. The
filamentwas advanced 1mm further until the ICAwas perforated
near its intracranial bifurcation. Subsequently, the filament was
withdrawn into the external carotid artery resulting in reperfusion
of the ICA and SAH. The duration of the endovascular occlusion
of the common carotid artery was at maximum 2–3 min.
At the end of the surgical preparation, wounds were closed
with filament sutures and anesthesia was antagonized by intra-
peritoneal injection of atipamezol (2.5 mg/kg; Pfizer, Karlsruhe,
Germany) and flumazenil (0.5 mg/kg; Hoffmann-La-Roche,
Grenzach-Wyhlen, Germany). The animals usually awakened
and regained normal motor function within 1–2 min.
Afterwards, animals were placed in individual cages and recov-
ered for 6 h in an incubator at 33 °Cwith 35%humidity (IC8000,
Draeger, Germany) in order to prevent hypothermia [10].
Oxygen-Glucose Deprivation (OGD)
Murine bEnd.3 cells (passage 23 to 30) were cultured in
Dulbecco’s modified Eagle’s medium supplemented with 15%
fetal calf serum (FCS), 100 IU/ml penicillin, and 100 μg/ml
streptavidin. Cells were grown in an incubator at 37 °C with
humidified (95%) air and 5% CO2. For experiments, 400,000
cells per well were seeded on poly-D-lysin coated 6-well plates.
After 24-h medium was supplemented with 10 μM 1-(5-
iodonapthalene-1-sulfonyl)-1H-hexahydro-1,4-diazepine hydro-
chloride (ML-7, Sigma-Aldrich, Germany) in dimethyl sulfoxide
(DMSO) orDMSO as vehicle control (0.1% final concentration).
After 30-min incubation, culture medium was removed, cells
were washed with PBS, and serum- and glucose-free DMEM
supplemented with DMSO or 10 μMML-7 (0.1% final DMSO
concentration). Hypoxic conditions (1% oxygen, 5% CO2) were
established for 4 h in a hypoxic chamber. After 15 min of reox-
ygenation, supernatant was removed, and cells werewashedwith
ice-cold PBS and lysed in 60 μl radioimmunoprecipitation assay
(RIPA) buffer (50 mM Tris-HCl, pH 7.5; 150 mM NaCl; 1 mM
EDTA; 1%NP-40; 0.1% sodiumdodecyl sulfate [SDS], protease
and phosphatase inhibitors [Roche]). Whole-cell lysates were
centrifuged at 14,000g for 20 min and 4 °C, and supernatants
were stored at − 80 °C until use.
Experimental Protocol
Investigators were blinded to the treatment given to the animals.
Mice were treated with intraperitoneal injection of the selective
MLCK inhibitor ML-7 (1 mg/kg) or vehicle solution (0.9%
NaCl) 1 h prior to and 6 h after SAH. ML-7 was stored as dry
powder at − 20 °C and freshly dissolved in normal saline before
use [7].
A. mRNA expression of MLCK, MLC, inflammatory cyto-
kines, and tight junction proteins were determined in an-
imals randomly assigned to three survival groups: SAH
12 and 24 h and sham-surgery (n = 8 each).
B. The effect of MLCK inhibition on ICP, neurological out-
come, and hemispheric brain water content was deter-
mined 24 h after SAH in animals randomized to (1) naive
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vehicle, (2) SAH+vehicle, (3) naive+ML-7, and (4)
SAH+ML-7 (n = 10 per group)
C. The effect of MLCK inhibition on BBB permeability
after SAH was determined via Evans blue extravasation
24 h after SAH in animals randomized to (1) naive+ve-
hicle, (2) SAH+vehicle, (3) naive+ML-7, and (4) SAH+
ML-7 (n = 7 per group). In addition, the ICP was mea-
sured 24 h after SAH.
D. The effect of MLCK inhibition on physiological param-
eters, neurological outcome, and histological damage
was determined 7 days after SAH via neuronal cell count
in the hippocampus of animals randomized to (1) naive+
vehicle, (2) SAH+vehicle, (3) naive+ML-7, and (4)
SAH+ML-7 (n = 11 per group).
E. The influence ofML-7 onMLCphosphorylation in hypoxic
brain endothelial cells (bEnd.3 cells) following 4-h brain-
glucose deprivation (OGD): (1) OGD+vehicle and (2)
OGD+ML7 (triplicates in two independent experiments).
Measurement of Physiological Parameters
Systolic blood pressure was non-invasively (NIBP) monitored
on the tail of the mice using a modified NIBP system (RTBP
2000, Kent, USA) as previously described [10]. Cuff pressure
signals were recorded with a sample rate of 100 Hz (A/D con-
verter: PCI 9112, Adlink Technology, Taiwan; PC software:
Dasylab 5.0, measX, Germany) and analyzed offline (Flexpro
6.0, Weisang, Germany) for systolic blood pressure and heart
rate. In all animals, NIBP was measured 5 min before and
5 min after SAH. In mice surviving 7 days NIBP were measured
daily.
In animals surviving 24 h, ICP values were determined and
blood samples were drawn from the carotid artery. Arterial blood
gas concentration, blood glucose levels, hematocrit, and electro-
lytes were determined with a blood gas analyzer (ABL800,
Radiometer Medical, Denmark).
Measurement of Brain Water Content
Twenty-four hours after SAH, mice were anesthetized by intra-
peritoneal anesthesia (midazolam, fentanyl, medetomidine).
After removal, brains were sectioned along the midsagittal plane
and the cerebellum removed. Each hemisphere was weighed and
then dried for 24 h at 110 °C to determine the dry weight. The
water content was assessed based on gravimetrical differences
[11].
Histological Evaluation
Seven days after SAH, mice were sedated by intraperitoneal
anesthesia (midazolam, fentanyl, medetomidine) and exsangui-
nated by transcardiac perfusion using 2% paraformaldehyde
(PFA) solution. The brains were carefully removed, post-fixed
in 2% PFA, and embedded in paraffin. Coronal sections (4 μm)
were cut at the level of the bregma (1.28, Mouse Brain Library
Atlas; www.mbl.org) in order to visualize the hippocampus and
subsequently stained with cresyl violet. An investigator blinded
to the experimental groups determined the neuronal cell count
(field 0.15 × 0.30mm) in the CA1, CA2, and CA3 regions of the
hippocampus.
Extravasation of Evans Blue
A previously reported quantitative assay was used to determine
Evans Blue levels in the ipsilateral hemisphere [7]. Three hours
after induction of SAH or in naive animals, 1 ml of 0.4% Evans
Blue (Sigma-Aldrich, Munich, Germany) was injected intraper-
itoneally. Twenty-four hours after SAH, animals were exsangui-
nated by transcardiac perfusion. A fluorescent plate reader (MRX
II, Dynex Technologies, Berlin, Germany) was used to measure
intracerebral Evans Blue dye concentrations at 630 nm. The
amount of extravasated Evans Blue was expressed as optical
density (OD) per gram of hemispheric brain tissue.
Quantification of Functional Outcome
Functional outcome before and after SAHwas determined by an
investigator blinded to the experimental groups. Body weight
and a neuroscore were assessed. The 31-point neuroscore, which
consists of tasks evaluating motor ability, alertness, balancing,
and general behavior, wasmodified on the basis of an established
protocol for rats [12] and the neurological scale of Bederson [13].
For each failed task, the mouse was assigned 1 point. Healthy
mice were successful in all tasks and received a score of 0
(Supplemental Table S1). Body weight was determined daily
and compared to values prior to SAH.
Gene Expression Analysis
The mRNA quantification by real-time quantitative polymerase
chain reaction (qPCR) was performed as previously described
[14]. In brief, RNAwas isolated from hippocampus and cortex
samples using Qiagen-RNeasy plus universal kit (Qiagen) and
reverse-transcribed into cDNAwithQuantiTect reverse transcrip-
tion Kit (Qiagen) according to the manufacturer’s instructions.
cDNA of each sample was amplified by real-time Lightcycler
480 PCR System (Roche). RT-PCR for the detection of
cyclophilin A (PPIA), myosin light chain kinase (MLCK) and
myosin light chain (MLC), interleukin 1β (IL-1β), tumor necro-
sis factor α (TNFα), interleukin 6 (IL-6), zonula occludens-1
(ZO-1), Claudin 5 (Cl5), and occludin (Ocln) was carried out
as previously reported using the real-time Lightcycler 480 PCR
system (Roche) [7]. Equal amounts of cDNA (1 μl) were used in
duplicates and amplified with Roche Lightcycler® 480 Probes
Master (PPIA, IL-1β, Ocln), 480 SYBRGreen IMaster (TNFα,
Transl. Stroke Res.
IL-6) or Thermo Scientific Absolute Blue SYBRGreen (MLCK,
MLC, ZO-1, Cl5). The absolute copy numbers of the target
genes were normalized against the absolute copy numbers of
PPIA as control gene.
Western Blot Analysis
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and immunoblotting were performed according
to standard procedures. Briefly, tissue samples were lysed in
RIPA buffer. Equal amounts of proteins (40 μg/lane), as deter-
mined by Lowry assay (Bio-Rad), were resolved by SDS-PAGE
(7.5% acrylamide for ZO-1 and MLCK; 12.5% acrylamide for
pMLC; 14% acrylamide for claudin-5). Membranes were incu-
bated with antibodies specific to claudin-5 (1:500, 35–2500,
Invitrogen), ZO-1 (1:500, 10,342,463, Fisher Scientific),
MLCK (1:3000, M7905, Sigma), phospho-MLC (1:400,
#3671s, cell signaling technologies) and GAPDH (1:10,000,
ACR001PT, Acris Antibodies), respectively, and appropriate
species-specific secondary infrared dye-conjugated antibodies
(1:15,000; Li-cor) to reveal protein band densities using the
Odyssey SA Imaging System and quantification with Image
Studio (both Li-cor).
Statistical Analysis
Statistical analysis was performed using Sigma Plot 13 software
package (Systat Software, USA). To determine the required sam-
ple size, an a priori power analysis using G*Power [15] was
performed using data from previously published studies. The a
priori power analysis for the effect size of 0.7 suggests that a
standard statistical power (1-β) of P = 0.95 for a given signifi-
cance level (α) of 0.05 and four experimental groups can be
obtained for brain damage with n= 11, brain water content with
n = 10, and BBB integrity with n = 7 subjects per group. Exact
Wilcoxon-Mann-Whitney tests were used for comparisons.
MLCK western blotting data was tested for outliers by Rout
outlier test (Q 1%). Based on the results, one data point was
removed from the ML-7 data set (Fig. 4). For each outcome,
p values were adjusted for multiple testing using Bonferroni-
Holm correction. Results are presented as mean ± standard devi-
ation (S.D.).
Results
Influence of SAH and ML-7 Application
on Physiological Parameters
Physiological parameters (pH, blood glucose level, hemoglobin,
hematocrit, and electrolyte levels) 24 h after SAH were within
normal range and showed no differences between experimental
groups (Table 1). Body temperature and systolic blood pressure
(Fig. 1a) during surgerywerewithin physiologic limits and stable
over the 7-day observation period in all groups (Fig. 1b). ML-7
administration had no influence on blood pressure, body weight,
or physiological parameters (pH, blood glucose level, hemoglo-
bin, hematocrit, and electrolytes).
Regional Cerebral Blood Flow and Intracranial
Pressure
Successful SAH induction was confirmed by a rapid increase in
ICP and decrease of CBF. Baseline ipsilateral regional CBF
values were obtained 10 min before the induction of SAH. In
all animals, SAH resulted in a CBF decrease to 20–30% of
baseline followed by gradual recovery over 15 min to 90% of
baseline. CBF data during surgery did not differ between vehicle
and ML-7-treated mice (Fig. 1c).
After vessel perforation, ICP values increased in all animals to
approximately 85mmHg and remained elevated at 25mmHg for
15 min (Fig. 1d). ICP data during surgery and until 15 min did
not differ between the SAH groups. After 24 h, ICP values of
ML-7-treated animals were significantly lower compared to
Table 1 Physiological
parameters Vehicle+SAH ML-7+SAH Vehicle native ML-7 native
pH 7.3 ± 0.1 7.4 ± 0.1 7.3 ± 0.1 7.3 ± 0.1
Hemoglobin (mg/dl) 13.2 ± 1.0 13.0 ± 0.8 12.7 ± 0.8 12.8 ± 0.6
HCT (%) 40.0 ± 3.1 40.0 ± 2.4 39.1 ± 2.4 39.4 ± 1.8
Na+ (mmol/dl) 133.3 ± 13.2 140.3 ± 11.0 131.0 ± 12.1 132 ± 18.1
Blood glucose levels (mg/dl) 404 ± 127 392 ± 35 273 ± 53.0 290 ± 18.2
Ca2+ (mmol/dl) 1.3 ± 0.1 1.4 ± 0.1 1.2 ± 0 0.8 ± 0
sysRR (mmHg) before SAH 139 ± 26 133 ± 29
sysRR (mmHg) after SAH 134 ± 29 128 ± 27
Rect. temp. (°C) during SAH 37.2 ± 0.3 37.4 ± 0.3
sysRR non-invasively determined systolic blood pressure, Rect. temp rectal temperature
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vehicle (SAH+vehicle 12.0 ± 3.6 mmHg; SAH+ML-7 5.7 ±
2.3 mmHg, Fig. 3d).
Influence of SAH on Ipsilateral Hippocampus mRNA
Expression
To determine the impact on the mRNA expression of key pro-
teins, qPCR was performed in hippocampal samples at 12 and
24 h after SAH and compared to the sham group (Fig. 2). In the
ipsilateral hippocampus, mRNA expression of MLCK increased
significantly compared to sham (24 h SAH 119 ± 10%, p < 0.05;
Fig. 2a). Analysis of tight junction protein mRNA expression
showed that claudin 5 (Cl5) expression was decreased 12 h after
SAH (12 h SAH74 ± 19%; Sham 100 ± 24%; p< 0.05 vs. sham;
Fig. 2b). As markers for inflammation, TNFα, IL-6, and IL-1β
expression was quantified. The expression of all genes was sig-
nificantly increased at 12 h after SAH in comparison to the sham
group (TNFα 501 ± 197%; IL-6 309 ± 159%; IL-1β 228 ± 89%;
p < 0.05 vs. sham; Fig. 2c). Twenty-four hours after SAH,
mRNA expression of IL-6 returned to sham level, whereas IL-
1β expression remained unchanged compared to 12 h post-SAH
(195 ± 82%; p< 0.05 vs. sham). TNFα mRNA expression was
lower compared to 12 h but still significantly higher compared to
sham values (194 ± 80%).
Effect of MLCK Inhibition on Brain Water Content 24 h
after SAH
Brain water content was determined as the wet/dry ratio in
naive mice and in SAH mice 24 h after surgery. In non-
operated animals, water content of both hemispheres was not
different between vehicle or ML-7 group (ipsilateral: naive+
vehicle 78.8 ± 0.3%; naive+ML-7 79.2 ± 0.2%, Fig. 3a; con-
tralateral: naive+vehicle 79.0 ± 0.2%; naive+ML-7 78.8 ±
1.1%). Twenty-four hours after SAH, brain water content in-
creased significantly in both hemispheres (ipsilateral: SAH+
vehicle 81.0 ± 0.6%; p = 0.021 vs. naive+vehicle; contralater-
al: SAH+vehicle 80.9 ± 0.6%; p = 0.021 vs. naive+vehicle;
Fig. 3a). In the presence of ML-7, increase of brain water
content was significantly less in the ipsilateral hemisphere
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Fig. 1 Systolic blood pressure, regional cerebral blood flow and
intracranial pressure. Non-invasively determined systolic blood pressure
(sysBP) did not differ between experimental groups during surgery (a)
and in the seven-day observation period (b). SAH resulted in a decrease
of cerebral blood flow (CBF, c) and an increase of intracranial pressure
(ICP, d). Within the next 15 min, CBF recovered to 90% of baseline (c)
and ICP remained elevated at 25mmHg (d). Data are presented as mean ±
S.D. and were not different between experimental groups
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(SAH+ML-7 79.9 ± 0.6%; p = 0.024 vs. SAH+vehicle; Fig.
3a). Water content of the contralateral hemisphere did not
differ between treatment groups (SAH+ML-7 80.5 ± 0.9%;
SAH+vehicle 80.9 ± 0.6%; Fig. 3a).
Blood-Brain Barrier Integrity 24 h after SAH
To further evaluate blood-brain barrier (BBB) integrity, the per-
meability to Evans blue dye was quantified. Specifically, Evans
blue dye was injected and quantified 24 h after SAH in both
hemispheres. In non-operated animals, Evans Blue extravasation
did not differ between ML-7 and the vehicle group (ipsilateral:
naive+vehicle 0.53 ± 0.14 OD/g; naive+ML-7 0.54 ± 0.1 OD/g,
Fig. 3b; contralateral: naive+vehicle 0.47 ± 0.06 OD/g; naive+
ML-7 0.53 ± 0.17 OD/g). After SAH, inhibition of MLCK with
ML-7 resulted in a significantly lower amount of Evans Blue in
both hemispheres compared to vehicle-treated animals (ipsilater-
al: SAH+vehicle 0.67 ± 0.15 OD/g; SAH+ML-7 0.48 ± 0.13
OD/g, p = 0.016; contralateral: SAH+vehicle 0.69 ± 0.20 OD/g;
SAH+ML-7 0.46+0.06 OD/g, p = 0.042, Fig. 3b).
Influence of MLCK Inhibition on Functional Outcome
and Intracranial Pressure 24 h after SAH
Neurological function was tested with a 31-point
neuroscore before surgery and 24 h after SAH (0 points =
no impairment and 31 points = maximum impairment). In
all groups, mice showed impairment after SAH.
Nevertheless, neurological outcome was significantly im-
proved in the ML-7 group (SAH+vehicle 6.6 ± 4.4 points;
SAH+ML-7 2.9 ± 1.7 points; p = 0.034; Fig. 3c).
In naïve animals and 15 min after induction of SAH,
intracranial pressure (ICP) was not different between ML-
7 and vehicle-treated animals. After 24 h, ICP values of
ML-7-treated animals were significantly lower than the
vehicle group (SAH+vehicle 12.0 ± 3.6 mmHg; SAH+
ML-7 5.7 ± 2.3 mmHg, p = 0.021; Fig. 3d).
Influence of MLCK Inhibition on Tight Junction
Proteins, MLC, and MLCK at 24 h After SAH
MLC and MLCK expression was determined 24 h after
SAH. MLC mRNA level was not different between ML-7
and vehicle-treated animals, whereas MLCK mRNA ex-
pression was significantly lower (SAH+ML-7 80 ± 14%,
mRNA expression level [% sham surgery]
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a Fig. 2 Influence of SAH onMLC andMLCK, tight junction protein, and
inflammation marker gene expression. To determine the impact of murine
SAH on mRNA expression of key proteins, qPCR was performed in
samples from hippocampus at 12 and 24 h after SAH and compared to
sham. In ipsilateral hippocampus, mRNA expression ofMLCK increased
significantly compared to sham (a). The analysis of tight junction protein
mRNA expression showed that the expression of claudin5 (Cl5) was
decreased 12 h after SAH (b). As markers for inflammation, TNFα, IL-
6, and IL-1βwere quantified. Expression of all genes peaked at 12 h after
SAH in comparison to sham-operated animals (c). Twenty-four hours
after SAH, mRNA expression of IL-6 returned to sham level, whereas
IL-1β expression remained un-changed compared to 12 h post-insult. The
expression of TNFα was lower compared to 12 h, but significantly com-
pared to sham. Data are presented as mean ± S.D.
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p < 0.05 vs. vehicle; Fig. 4a). However, on the protein
level, MLCK signal was significantly enhanced in ML-
7-treated animals (Fig. 4b).
To identify the relationship between tight junction re-
modeling and BBB integrity, mRNA expression of the
tight junction proteins zonula occludens-1 (ZO-1), claudin
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Fig. 3 Influence of MLCK inhibition on brain edema formation, BBB
integrity, functional outcome, and intracranial pressure. (a) Influence of
MLCK inhibition by selective blockage with ML-7 on brain edema
formation was examined by wet-dry ratio 24 h after SAH. Following
SAH brain water content increased in vehicle treated animals. Twenty-
four hours after SAH, brain water content was lower in ML-7-treated
animals. (b) BBB functionality was assessed by Evans blue
extravasation 24 h after SAH. Inhibition of MLCK resulted in less
intracerebral Evans blue compared to vehicle-treated animals. (c)
Neurological function was determined with a 31-point neuroscore and
shows a less functional impairment in ML-7-treated animals. (d)
Twenty-four hours after SAH ICP of ML-7-treated animals were lower
compared to the vehicle group. Data are presented as mean ± S.D. NS not
significant
Transl. Stroke Res.
5 (Cl5), and occludin (Ocld) was analyzed 24 h after SAH
in animals treated with vehicle or ML-7. In the ipsilateral
hippocampus ZO-1, Cl5 and Ocld expression increased in
response to ML-7 treatment (SAH+ML-7: Cl5 117 ± 18%;
Ocld 144 ± 40%; ZO-1 115 ± 19%, p < 0.05 vs. SAH ve-
hicle; Fig. 4c). In contrast to mRNA expression, ZO-1 and
Cl5 protein levels (Fig. 4d) were not different between
ML-7- and vehicle-treated animals.
Influence of MLCK Inhibition on Protein Expression
in Brain Endothelial Cells
Unexpectedly, ML-7 increased MLCK protein levels after
SAH. To rule out that this regulation in turn alleviates the
effect of ML-7 on MLCK, we subjected brain endothelial
cells (bEnd.3 cells) to 4 h of OGD in the presence of
either the MLCK inhibitor ML-7 or vehicle solution.
Four hours of OGD resulted in visible shrinkage of the
cells (Fig. 5a), which appeared to be less pronounced in
bEnd.3 cells treated with ML-7 (Fig. 5b) suggesting less
contraction and activation of the contractile apparatus.
Next, we determined the key target proteins of ML-7,
pMLC, and MLCK. The phosphorylated MLC (pMLC)
protein signal was significantly decreased in ML-7-
treated cells (OGD+ML-7 77 ± 10% vs. vehicle; p <
0.01; Fig. 5c). Similar to ML-7-treated animals, MLCK
protein levels was (by trend) higher in ML-7-treated cells
(OGD+ML-7 154 ± 38%; p = 0.056 vs. vehicle; Fig. 5d).
This MLCK regulation did not influence the effect of ML-
7 on pMLC levels and cell shape in bEnd.3 cells subject-
ed to OGD.
Influence of MLCK Inhibition on Functional Outcome
and Mortality over 7 Days Following SAH
Neurological function was tested with a 31-point
neuroscore before and at day 1, 2, 3, 5, and 7 following
SAH. In all experimental groups, animals showed impair-
ment after SAH, but recovered within 72 h. The adminis-
tration of ML-7 significantly improved neurological func-
tion 24 and 48 h after SAH (24 h: SAH+vehicle 7.3 ± 5.3
points; SAH+ML-7 5.8 ± 4.4 points, p = 0.038; 48 h:
SAH+vehicle 4.3 ± 4.0 points; SAH+ML-7 1.1 ± 1.9
points, p = 0.012; Fig. 6a). Independent of the treatment
arm, animals lost 13% of body weight within 24 h after
SAH. Weight loss reached a maximum on the third day
mRNA expression level [%SAH vehicle]
MLCK
MLC
SAH vehicle
SAH ML-7
Mean ± S.D.; *p<0.05 vs. SAH vehicle
*
mRNA expression level [% SAH vehicle]
Cl5
Ocld
ZO-1
SAH vehicle
SAH ML-7
Mean ± S.D.; *p<0.05 vs. SAH vehicle
*
*
*
a
c
Protein signal level [%SAH vehicle]
MLCK
SAH vehicle
SAH ML-7
Mean ± S.D.; **p<0.01 vs. SAH vehicle
**
Protein signal level [% SAH vehicle]
0 20 40 60 80 100 120 140
0 50 100 150 200
0 50 100 150 200 250 300
0 50 100 150 200
Cl5
ZO1
SAH vehicle
SAH ML-7
Mean ± S.D.
b
d
Fig. 4 Influence of MLCK inhibition on MLC, MLCK, and tight
junction mRNA and protein levels. Twenty-four hours after SAH, brain
tissue was sampled from mice with ML-7 and vehicle treatment to
determine mRNA and protein levels of MLC, MLCK, and tight
junction proteins. (a) MLC mRNA levels were not influenced by ML-
7, whereas MLCK mRNA expression decreased significantly. (b) In
contrast to mRNA data, MLCK protein levels were twofold in ML-7-
treated animals. (c) Tight junction proteins ZO-1, claudin 5 (Cl5), and
occludin (Ocld) mRNA expression levels increased significantly in
response to ML-7. (c) In contrast, ZO-1 and Cl5 protein levels were not
significantly influenced by ML-7. Data are presented as mean ± S.D.
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(− 19%). Thereafter, mice regained body weight to values
prior to SAH. No differences were present between
groups (data not shown).
The mortality rate of the vehicle group was 27% (3/11)
7 days post-SAH, in agreement with our previously pub-
lished results in C57BL6 mice [9]. ML-7 significantly
reduced mortality rate to 9% (1/11; p = 0.041, Fig. 6b).
Influence of MLCK Inhibition on Neuronal Cell Count
7 Days after SAH
We analyzed the influence of reduced brain edema and intra-
cranial pressure on neuronal brain damage. Neuronal cell
count in hippocampus (CA1–3) at day 7 after SAH was not
different between the experimental groups (data not shown).
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Fig. 5 Influence of ML-7 on MLC phosphorylation and MLCK protein
levels. To determine the influence of ML-7 in brain endothelial cells,
bEnd.3 cells were subjected to 4 h OGD. (a) OGD resulted in
pronounced cell shrinkage (white arrows). Pictures show endothelial cells
at × 4 and × 10 magnification. (b) In the presence of ML-7, cells
demonstrate less shrinkage pattern. (c) In ML-7-treated cells,
phosphorylated MLC (pMLC) protein signal was significantly lower,
whereas (d) MLCK protein level was by trend higher in ML-7-treated
cells. Data are presented as mean ± S.D.
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Only one mouse in the vehicle group exhibited pronounced
neuronal death in the hippocampal regions CA1–3 and corti-
cal brain tissue, suggesting a focal damage produced by the
ICP sensor.
Discussion
Brain edema formation plays an important role in the patho-
physiology of ischemia-induced brain injury. However, the
mechanisms by which vascular cells contribute to the break-
down of the blood-brain barrier (BBB) in SAH remain elu-
sive. We demonstrate for the first time that blocking the intra-
cellular contraction apparatus with a myosin light chain kinase
inhibitor (1) preserves blood-brain barrier integrity, (2) re-
duces brain edema formation, (3) decreases elevated intracra-
nial pressure, (4) improves neurological function, and (5) re-
duces mortality following SAH.
The murine endovascular perforation model used in the
current study replicates the key features of human SAH. The
model causes delayed cerebral vasospasm, neurological dys-
function, brain edema, and a mortality of ∼ 30% [9, 16–18].
Cerebral brain edema is considered the cardinal pathophysio-
logical event underlying cell death and severe complications
after SAH [1]. The initial rise of ICP and decrease of CBF are
initiating factors for the development of cytotoxic edema.
Persistent ischemia gives rise to endothelial apoptosis and
breakdown of the BBB. Disruption of the BBB results in
vasogenic edema, which leads to further increase of ICP and
reduction of CBF [3]. The mechanisms of BBB disruption
after SAH, especially the role of the endothelial barrier, are
still unclear.
The BBB comprises endothelial cells, pericytes, and astro-
cytes. Cerebral endothelial cells are joined by tight junctions,
which ensure the integrity of the BBB and limit paracellular
influx of hydrophilic molecules across the BBB. SAH in-
creases the permeability of the BBB, which permits extrava-
sation of water into the brain [19]. Increased permeability
could be a result of the activation of the contractile apparatus.
The contractile apparatus of, e.g., endothelial cells is directly
connected to tight junction proteins. Therefore, the integrity of
the BBB may be influenced by an upregulation of MLCK,
which leads to increased phosphorylation of MLC. In turn,
MLC phosphorylation facilitates cytoskeletal rearrangement,
which may reduce endothelial cell-to-cell contact [20]. The
hypothesis is supported by previous findings that hypoxic-
dependent activation of the MLCK leads to increased perme-
ability of endothelial cells and to increased MLC phosphory-
lation. Importantly, administration of the MLCK inhibitor
ML-7 counteracts both adverse events. In addition, ML-7 sig-
nificantly reduces brain water content in a two-vein occlusion
stroke model and after traumatic brain injury [4, 7]. These
results are consistent with the present study where inhibition
of MLCK stabilized BBB and prevented brain edema forma-
tion 24 h after SAH. Reduced brain edema was accompanied
by a significant reduction in ICP that improved outcome and
reduced mortality.
Our data indicate that mRNA expression of MLCK is in-
creased after SAH compared to sham surgery and that selec-
tive MLCK inhibition after SAH improves outcome of SAH.
Other groups have not reported a difference in the myosin
light chain kinase activity of canine basilar artery between a
control study and two models of SAH for up to 10 days after
intracisternal injection of blood [21]. Whereas there is no in-
creased activity of MLCK in the basilar artery, the regulatory
pathway of Ca2+-calmodulin-MLCK is the major candidate
for arterial vasospasm after SAH. Phosphorylation of MLC
is increased during vasospasm after SAH in the anterior spinal
artery [22] and basilar artery [23]. In addition, vasospasm is
reversed by the topical application of MLCK inhibitor ML-9
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Fig. 6 Influence of ML-7 on mortality rate and neurological recovery
after SAH. Mice were subjected to SAH and treated with ML-7 or
vehicle. (a) Neurological function was quantified with a 31-point scale
during the 7-day observation period. ML-7-treated animals exhibited less
neurological deficits on days 1 and 2 compared with vehicle. (b)
Mortality rate (Kaplan-Meier curve) was significantly lower in ML-7-
treated animals after SAH. Data are presented as mean ± S.D. NS not
significant
Transl. Stroke Res.
[24]. To demonstrate the influence of ML-7 on endothelial
cells, we performed in vitro OGD experiments. In these cells,
post-hypoxic shrinkage of the cellular shape was reduced by
ML-7. In line with the visual changes in cell form, we show
that inhibition of MLCK reduced the phosphorylation of
MLC. The data support the assumption that post-ischemic
activation of MLCK results in cytoskeletal rearrangement
and reduced endothelial cell-to-cell contact and tightness of
the blood-brain barrier integrity.
In addition, we investigated the morphological features of
brain damage. We hypothesized that pronounced reduction in
ICP combined with brain edema should result in not only
functional impairment but also histological evidence of injury.
Unfortunately, only one mouse in the vehicle group exhibited
histopathological signs of substantial neuronal death. The
shape of the morphological brain damage suggests that the
damage was caused by the ICP sensor. At 7 days post-SAH,
there was no reduction in the neuronal cell count in the hip-
pocampus. We cannot rule out, however, that damaged neu-
rons were not sampled or visualized using standard light mi-
croscopic methods. However, similar results were reported by
other groups using experimental endovascular models in, e.g.,
rats [25]. Although the present model failed to produce
sustained substantial neuronal cell loss, other features of
SAH such as increase in ICP, drop in CBF, neurological def-
icits, and pronounced brain edema were reliably reproduced.
The present study may be limited by the fact that integrity
of the BBB was only investigated within 24 h after SAH. In
the literature, increased brain water content was found in the
cortex 24 to 48 h after SAH with a peak at 24 h [26, 27].
Microvascular basal lamina damage was demonstrated from
24 to 72 h after SAH [26]. In the present study, we aimed to
investigate brain edema at its peak and, therefore, at 24 h.
Furthermore, no time points later than 7 days after SAH were
investigated, because neurological function and histopatho-
logical damage did not reveal significant differences 7 days
after SAH.
Unexpectedly, MLCK protein levels were increased by
ML-7 in animals and by trend in the in vitro experiments. In
the endothelial cells, we were able to demonstrate that higher
MLCK levels did not have an effect on pMLC levels and that
ML-7 retained its effect on MLCK and pMLC. We therefore
postulate that the MLCK upregulation is a compensatory reg-
ulation, which may represent regulation on protein level to
reestablish higher pMLC levels. The influence of ML-7 on
pMLC was determined in brain endothelial cells in vitro. We
therefore cannot rule out that the in vivo regulation may be
different.
In addition, MLCK is not only expressed in endothelial
cells but also in various cell types (for review please see
[28]) in the brain. It is also found in astrocytes [29], neurons
[30], and microglia [31]. ML-7 targets MLCK in all cells and
has even effects on Ca2+ currents in pericytes [32]. The effect
of ML-7 is therefore not limited to endothelial cells. However,
the endothelial layer is the most important barrier to seal the
brain from the circulation.
In summary, the present study indicates that the endothelial
cell cytoskeleton plays a critical role in barrier function and
integrity of the BBB. By selectively inhibiting MLCK with
ML-7, we have demonstrated that the endothelial cytoskeleton
contributes to increased permeability of the BBB after SAH
and vasogenic edema formation. The present data therefore
provide convincing evidence of the interplay between endo-
thelial dysfunction with tightness of the neurovascular unit.
Accordingly, MLCK may serve as a promising target for the
treatment of vasogenic brain edema after SAH.
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